The University Hospital Cologne is involved in the new European Vaccines Hub

The European Commission is funding the initiative via the EU4Health program with over 100 million euros over a period of four years. The German Center for Infection Research (DZIF) is playing a central role, including Cologne University Hospital.

The EVH's focus is on developing scalable vaccine and antibody platforms against priority pathogens. The EVH unites 24 institutions from seven countries and is divided into four central pillars — from basic research and preclinical studies to clinical studies and production. The DZIF is involved in nearly all work packages.

Under the direction of Prof. Dr. Florian Klein, Director of the Institute of Virology at Cologne University Hospital and Executive Board Member at the Center for Molecular Medicine Cologne (CMMC), the hospital is contributing its extensive expertise in developing human monoclonal antibodies to the project. Around 21 million euros will be allocated to German institutions under the DZIF umbrella. The EVH will also collaborate closely with HERA (Health Emergency Preparedness and Response Authority), the European pandemic preparedness authority.

This message has been modified by the CMMC (K. Heber & D. Grosskopf-Kroiher) and is based on the text by the press and communications team of the University Hospital Cologne (original version in German here).